Hofseth BioCare ASA is yet again part of an Exclusive Short-List of Companies to Have Successfully Notified FDA while receiving a No Objection Letter for ProGo® Bioactive Peptides. Summary Highlights of the FDA's NDI Process for HBC and what it means: The FDA's NDI notification process is the only pre-market gate for demonstrating identity, safety, and even cGMP quality for both dietary supplements and/or dietary ingredients contained in dietary supplements that are new to the US marketplace. - The NDI letter for ProGo® is the highest safety rating and attestation the company could have received from the FDA.

This achievement follows on the heels of successful receipt of the same accolades for both CalGo® and OmeGo® late last year. Today, HBC's entire portfolio of human food-grade ingredients has received FDA's No Objection Letter, also called an "Acknowledgement Without Comment" Letter or Acknowledgement (AKL) Letter. The historical acknowledgment rate of NDI notifications by the FDA is low (approximately 30%), prompting food companies to choose the easier self-GRAS conclusion pathway.

After rigorous review by FDA scientists (NDI Review Team), ProGo® is permitted to deliver up to 24 grams/day in adults (excluding pregnant women), significantly in excess of the maximum daily dose used on all the clinical trials.